Peptides May Spark a New Boom in Telehealth Sales

The Food and Drug Administration is poised to determine whether specialty pharmacies can legally combine seven newly approved peptide drugs—a move that could unlock a vast market for telehealth providers.

What Are Peptides?

Peptides are tiny protein fragments injected to accelerate recovery, boost energy, or slow aging. Two years ago pharmacies began producing cheaper versions of Ozempic, spawning a multibillion‑dollar shadow industry. Now the same model may extend to wellness peptides like BPC‑157 and TB‑500, popular among biohackers.

Telehealth Companies on the Brink

Hims & Hers profited from pharmacy‑mixed Ozempic and Wegovy.
After the FDA declared those drugs no longer “short,” Hims pivoted its business model.
The company’s chief medical officer will testify before the FDA, expressing intent to add peptides to its portfolio and citing potential health benefits.

Market Size & Competition

Wheel, a telehealth infrastructure provider, predicts that FDA approval will prompt large players to source peptides from reputable pharmacies.
Research estimates the addressable peptide market—including illicit and off‑label use—at $30 billion.

Safety Concerns

Unlike Ozempic, users often mix multiple peptides simultaneously. Because these combinations lack large, controlled trials, long‑term safety remains unknown. The FDA’s ruling will decide whether peptide demand stays within a regulated, doctor‑led system or continues in the gray market.

Future Outlook

Wheel’s CEO forecasts a wave of new telehealth sites launching peptide programs next year, mirroring how over 80 Shopify founders opened GLP‑1 clinics by late 2024.
Larger, well‑funded platforms will likely outcompete smaller operators on price and credibility, forcing the latter to be acquired or shut down.

Stakeholder Perspectives

Torch Capital’s founder argues that compliance benefits all: consumers receive safe, correctly dosed products; legitimate operators build lasting businesses; and regulators can monitor the market.
He believes that regardless of the FDA’s vote, peptide demand will persist—only shifting into a more controlled channel.